Adolfo López de Munain
Dr. López de Munain is Chief Scientific Officer and Co-Founder of Miramoon Pharma, with over 35 years of experience in clinical neurology, neurogenetics, and translational neuroscience. He holds an MD and a PhD in Medicine from the University of Navarra, where he conducted his doctoral research on myotonic dystrophy.
His scientific career has focused on the molecular and clinical bases of neurogenetic disorders, with major contributions in neuromuscular and neurodegenerative diseases including ALS, Parkinson’s disease, prion diseases, and frontotemporal dementias. He has coordinated large national and international research programs, led multicenter clinical trials, and established research networks.
Dr. López de Munain is Principal Investigator of the Donostia group at the Center for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED), where he has served as Scientific Director since 2020. He is also member of the Steering Committee of the Basque Biobank, the Board of the Matia Foundation, and the Health and Quality of Life Division of TECNALIA.
He has authored over 350 peer-reviewed publications, 26 book chapters, and more than 400 conference presentations (H-index 71), and has supervised 22 PhD theses. An active member of the Spanish Society of Neurology, he has chaired its Basque regional branch and coordinated its study groups on Neuromuscular Diseases and Neurogenetics.
Dr. López de Munain is also Associate Professor of Neurology at the University of the Basque Country and the University of Deusto. He co-founded the Ilundain Foundation, MIAKER Developments, and Athenea Neuroclinics, and in 2019 co-founded Miramoon Pharma to advance innovative therapies for central nervous system and neuromuscular disorders. He received the 2022 Biomedical Research Award from the Spanish Society of Neurology.
